Freise, Noemi F. and Gliga, Smaranda and Fischer, Johannes and Lubke, Nadine and Lutterbeck, Matthias and Scholer, Miriam and Bolke, Edwin and Orth, Hans Martin and Feldt, Torsten and Roemmele, Christoph and Wilke, Dominik and Schneider, Jochen and Wille, Kai and Hohmann, Christian and Strauss, Richard and Hower, Martin and Ruf, Andreas and Schubert, Joerg and Isberner, Nora and Stecher, Melanie and Pilgram, Lisa and Vehreschild, Jorg J. and Hanses, Frank and Luedde, Tom and Jensen, Bjorn (2022) Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort. SCIENTIFIC REPORTS, 12 (1): 19035. ISSN 2045-2322,
Full text not available from this repository. (Request a copy)Abstract
Establishing the optimal treatment for COVID-19 patients remains challenging. Specifically, immunocompromised and pre-diseased patients are at high risk for severe disease course and face limited therapeutic options. Convalescent plasma (CP) has been considered as therapeutic approach, but reliable data are lacking, especially for high-risk patients. We performed a retrospective analysis of 55 hospitalized COVID-19 patients from University Hospital Duesseldorf (UKD) at high risk for disease progression, in a substantial proportion due to immunosuppression from cancer, solid organ transplantation, autoimmune disease, dialysis. A matched-pairs analysis (1:4) was performed with 220 patients from the Lean European Open Survey on SARS-CoV-2-infected Patients (LEOSS) who were treated or not treated with CP. Both cohorts had high mortality (UKD 41.8%, LEOSS 34.1%). A matched-pairs analysis showed no significant effect on mortality. CP administration before the formation of pulmonary infiltrates showed the lowest mortality in both cohorts (10%), whereas mortality in the complicated phase was 27.8%. CP administration during the critical phase revealed the highest mortality: UKD 60.9%, LEOSS 48.3%. In our cohort of COVID-19 patients with severe comorbidities CP did not significantly reduce mortality in a retrospective matched-pairs analysis. However, our data supports the concept that a reduction in mortality is achievable by early CP administration.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | IMMUNOCOMPROMISED PATIENTS; COVID-19; THERAPY; CELL; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Notfallambulanz |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2023 07:45 |
| Last Modified: | 14 Dec 2023 07:45 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58665 |
Actions (login required)
 |
View Item |
